[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Simron Singh, Daniel Halperin, Sten Myrehaug, Ken Herrmann, Marianne Pavel, Pamela L. Kunz, Beth Chasen, Salvatore Tafuto, Secondo Lastoria, Jaume Capdevila, Amparo García-Burillo, Do-Youn Oh, Changhoon Yoo, T. Halfdanarson, Stephen Falk, I. Folitar, Yufen Zhang, Paola Aimone, W. W. D. Herder, D. Ferone
{"title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","authors":"Simron Singh, Daniel Halperin, Sten Myrehaug, Ken Herrmann, Marianne Pavel, Pamela L. Kunz, Beth Chasen, Salvatore Tafuto, Secondo Lastoria, Jaume Capdevila, Amparo García-Burillo, Do-Youn Oh, Changhoon Yoo, T. Halfdanarson, Stephen Falk, I. Folitar, Yufen Zhang, Paola Aimone, W. W. D. Herder, D. Ferone","doi":"10.1016/S0140-6736(24)00701-3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":510912,"journal":{"name":"The Lancet","volume":"2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/S0140-6736(24)00701-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
